



Pixium Vision presents at Ophta Biotech, annual conference on ophthalmic innovations

Pixium Vision strengthens its relationships with visually impaired patient associations

Paris and Marseille - October 28, 2014 – Pixium Vision (FR0011950641 - PIX), a company developing innovative Vision Restoration Systems (VRS) to allow patients who have lost their sight to lead more independent lives, announces its participation to the annual conference on ophthalmic innovations organized by Ophta Biotech, a collaborative platform to serve visually impaired patients.

The presentation of the company and its innovations in a program dedicated to "Visual impairment and return to sight" showcases the importance of close partnership between vision specialists, patient associations and the industry to develop and bring innovative Vision Restoration Systems to the market.

Khalid Ishaque, CEO of Pixium Vision said: *"It is vital for Pixium Vision, with initiation of commercial launch preparation for IRIS[®], its first Vision Restoration system, to strengthen its ties with the foundations and patient associations. They are the voice of patients and play an essential role in the awareness and adoption of new therapeutic solutions that improve independence, mobility and quality of life of blind patients".*

About Ophta Biotech

Ophta Biotech is a unique structure in Europe that brings together ophthalmology players in the field of diagnostics, therapeutics and research with patient associations. Supported by the "Pôle Santé" Eurobiomed, Ophta Biotech brings together public and private organizations, hospitals, research centres and associations of visually impaired patients.

The goal of Ophta Biotech is to promote the emergence of specific therapeutic solutions to improve the quality of life of patients suffering from vision disorders. Researchers, clinicians and industry players will present to their peers and to representatives of patient associations, the latest technological developments and support schemes to improve the daily lives of visually impaired patients both in terms of autonomy and safety.

About Pixium Vision

Pixium Vision is developing innovative Vision Restoration Systems (VRS) that aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. Pixium Vision's VRS are

composed of various high-tech elements, associated with a surgical intervention as well as a rehabilitation period. These systems aim to ultimately provide blind patients with vision approaching that of a normal healthy eye.

Clinical trials are currently underway with the VRS IRIS[®] in several centers in Europe. Patients have tolerated their implants well so far and improvements in visual perception have been observed. The results of these studies will be used to apply for CE mark. Commercialization of IRIS[®] is expected to begin in 2015.

Pixium Vision is also developing PRIMA, a sub retinal implant currently in preclinical trial. The Company plans to begin clinical trials of PRIMA in Europe in 2016.



Pixium Vision is listed on Euronext (Compartment C) in Paris.
ISIN: FR0011950641; ticker: PIX

IRIS[®] is a trademark of Pixium-Vision SA

Contacts

Pixium Vision

Pierre Kemula, CFO

contact@pixium-vision.com

+33 1 76 21 47 30

Investors Relations / Press Relations

Citigate Dewe Rogerson

Lucie Larguier – Laurence Bault (Paris)

Mark Swallow – David Dible (London)

pixium-vision@citigate.fr / pixium-vision@citigatedr.co.uk

+33 1 53 32 84 78 / +44 20 7282 2948

Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward-looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Documents de Base filed with the AMF under number I. 14-030 on May 12, 2014 and Chapter 2 "Risk Factors related to the Offer" in the prospectus, which can be found on the websites of the AMF - AMF (www.amf-france.org) and Pixium Vision (www.pixium-vision.com).